Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for oncology and autoimmune and inflammatory diseases. News commonly centers on bexobrutideg (NX-5948), a Bruton’s tyrosine kinase degrader, including clinical data in chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, as well as updates tied to the DAYBreak development program.
Company updates also cover Nurix’s DEL-AI discovery platform, preclinical degrader programs against targets such as pan-mutant BRAF, CBL-B and Aurora kinase A, and partnered inflammation and immunology programs involving IRAK4 and STAT6 degraders. Recurring announcements include financial results, corporate presentations, scientific meeting data, pipeline progress, capital actions and board or governance changes.
Nurix Therapeutics (Nasdaq: NRIX) reported new preclinical and Phase 1 translational data for its oral BTK degrader bexobrutideg (NX-5948) in chronic spontaneous urticaria (CSU). Data show potent, highly selective BTK degradation across key immune cells and rapid, robust BTK loss in blood and skin of healthy volunteers.
According to Nurix, bexobrutideg achieved ~25-fold greater potency than remibrutinib in preclinical FcεRI-driven models and produced larger reductions in ear swelling and vascular permeability in a mouse anaphylaxis model, supporting further clinical development in CSU and broader inflammation and immunology indications.
Nurix Therapeutics (Nasdaq: NRIX) announced that president and CEO Arthur T. Sands will join fireside chats at two upcoming investor conferences.
He is scheduled for the RBC Global Healthcare Conference on May 20, 2026 at 1:30 p.m. ET and the Jefferies Global Healthcare Conference on June 3, 2026 at 11:05 a.m. ET. Live and archived webcasts will be accessible for 30 days in the Investors section of Nurix's website.
Nurix Therapeutics (Nasdaq: NRIX) announced that updated efficacy and safety data from its ongoing Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in chronic lymphocytic leukemia (CLL) will be presented in an oral session at the 31st European Hematology Association Congress (EHA2026) in Stockholm, Sweden, on June 14, 2026.
Nurix Therapeutics (Nasdaq: NRIX) disclosed preclinical and early clinical data at AACR 2026 across three oncology programs: pan-mutant BRAF (NRX-0305), CBL-B (NX-1607), and AURKA (NRX-4972).
Key findings include a 142% lifespan increase for NRX-0305 in a BRAF inhibitor–resistant brain metastasis PDX, activity across 14 BRAF PDX models, sub-nanomolar CBL-B inhibitor binding with pharmacodynamic biomarker modulation in patients, and superior SCLC survival with NRX-4972 versus AURKA inhibitors.
Nurix Therapeutics (Nasdaq: NRIX) reported Q1 2026 results and program milestones. Key clinical moves include ongoing Phase 2 DAYBreak CLL-201 to support Accelerated Approval, a planned Phase 3 DAYBreak CLL-306 to start midyear 2026, and a 2026 IND target for a tablet bexobrutideg in immunology.
Financials: revenue $6.3M, R&D $84.1M, net loss $87.2M, and cash and marketable securities $540.7M as of February 28, 2026.
Nurix Therapeutics (Nasdaq: NRIX) announced that Arthur T. Sands, M.D., Ph.D., president and CEO, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, 1:30–2:10 p.m. ET.
The session will be webcast live and the archived webcast will be available via the Investors section of the Nurix website for 30 days after the event.
Nurix Therapeutics (Nasdaq: NRIX) will present two oral talks and three poster presentations at the AACR 2026 Annual Meeting April 17–22 in San Diego. Presentations focus on CBL-B, AURKA and mutant BRAF targets and orally bioavailable degraders. Gwenn Hansen, Ph.D., will speak April 22 in an Advances session on induced proximity pharmacology.
Nurix (Nasdaq: NRIX) reported Q4 and FY2025 results and operational milestones on January 28, 2026. Key clinical advances include an 83% ORR and median PFS 22.1 months for bexobrutideg in relapsed/refractory CLL and initiation of the DAYBreak™ pivotal Phase 2 program at 600 mg once daily. Corporate actions include a $250.0 million registered offering and cash and marketable securities of $592.9 million as of Nov 30, 2025.
FY2025 revenue was $84.0 million; R&D expense rose to $316.9 million and net loss was $264.5 million.
Nurix (NASDAQ: NRIX) outlined 2026 objectives to advance its BTK degrader bexobrutideg through pivotal development in relapsed/refractory CLL, including the ongoing Phase 2 DAYBreak CLL-201 (600 mg once daily) and a planned confirmatory Phase 3, DAYBreak CLL-306, versus pirtobrutinib. Clinical updates reported an 83% objective response rate and median progression-free survival of 22.1 months in heavily pretreated CLL cohorts. Nurix is also testing a tablet formulation to support INDs in autoimmune/inflammatory indications in 2026, advancing partnered degrader programs (IRAK4 with Gilead; STAT6 with Sanofi), and reported pro forma cash/investments of $663.8M after a $250M registered offering in Oct 2025.
Nurix Therapeutics (Nasdaq: NRIX) announced that Arthur T. Sands, M.D., Ph.D., president and CEO, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 4:30 p.m. PT in San Francisco.
The presentation will be webcast live and accessible via a link in the Investors section of the Nurix website, with the archived webcast available for 30 days after the event.